Service Communautaire d'Information sur la Recherche et le Développement - CORDIS

ERC

Porous Silicon Nanov Résumé de rapport

Project ID: 310892
Financé au titre de: FP7-IDEAS-ERC
Pays: Finland

Mid-Term Report Summary - POROUS SILICON NANOV (Multistage-Multifunctional Porous Silicon Nanovectors for Directed Theranostics)

The progress of nanotechnology during the last few decades has had a strong impact on the current research of biomedical applications, in particular against diseases such as cancer. It is estimated that more than 12 million cases of cancer are diagnosed every year worldwide. Multidrug resistance, rapid elimination by the immune system, enzymatic degradation and poor targeting efficiency are still the major obstacles of the nanomedicines used in cancer therapy. Nanocarriers are currently being widely investigated as a potential solution to improve the solubility of poor water soluble drugs and for delivering the drugs to target sites.

This project aims to develop novel nanomedicines for cancer therapy. Specifically, the project will be using porous silicon-based nanomaterials, a form of silicon that has nanoholes in its nanostructure. By precisely engineering and modifying this material, it is possible to use it as a highly effective platform for delivering drug molecules to very specific areas of the body. The severe side effects of cancer-fighting drugs are well documented, thus by delivering the nanopatforms to the cancer cells and ensuring that healthy cells remain unaffected by them, the effectiveness of these nanomedicines can be greatly enhanced.

So far, a novel multi-stage nanosystem has been developed using an advanced microfluidic technique. This was achieved by incorporating the porous nanomaterials inside another nanostructure, forming a ‘nano-in-nano’ composite. The precise targeting of the system was achieved by modifying the outer layer of the nanocomposite so that it can attach precisely to surface receptors specific to cancer cells, after which the nanocomposite is incorporated itself inside the cells and releases the drug therein. The outer surface layer of the nanocomposite then disintegrates, releasing the second stage of our nanosystem that carries the drug molecules designed to kill the cancer cells. The development and optimization of multistage–multifunctional nanoplatform has already been tested both in vitro and in vivo. Furthermore, this versatile multicomposite nanovectors have been shown to possess precise controlled drug delivery for simultaneously encapsulating different cargos and possessing surfaces readily for specific biofunctionalization and demonstrated to reduce cancer tumors, which represents a promising platform for future targeted combination therapy.

Contact

Pilvi Toppinen
Tél.: +358505447616
E-mail
Numéro d'enregistrement: 183426 / Dernière mise à jour le: 2016-05-26
Source d'information: SESAM